Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024. In the quarter to June 2026, revenue grew 45.4%, EPS grew 100.0%, free cash flow grew 8.47% and total debt rose 5.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CAI
Caris Life Sciences,�Inc. (CAI) P/E ratio
As of 16 October 2026, Caris Life Sciences,�Inc. (CAI) trades at a P/E ratio of 81.3×. Over the past ten years it has ranged from 0.0× (June 2026) to 85.8× (September 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 47.4× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ABVX Abivax SA Sponsored ADR compare | n/m |
| CYTK Cytokinetics, Incorporated compare | n/m |
| KYMR Kymera Therapeutics, Inc. compare | n/m |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | n/m |
| AXSM Axsome Therapeutics, Inc. compare | n/m |
| TGTX TG Therapeutics, Inc. compare | 17.8× |
| KRYS Krystal Biotech, Inc. compare | 38.3× |
| CAI Caris Life Sciences,�Inc. | 81.3× |
| PTGX Protagonist Therapeutics, Inc. compare | 106× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)